



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Briobacept

Cat. No.:	HY-P99487
CAS No.:	869881-54-9
Target:	ADC Antibody
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3) and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA) ^{[1][2]} .
IC₅₀ & Target	BLyS (BAFF) ^[1]
In Vitro	Briobacept blocks circulating BLyS, thus inhibiting B cell activation and promoting B cell apoptosis ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Briobacept (100 µg/mouse; i.p.; for 5 d) inhibits basal NF-κB2 activation in wild-type mice ^[4] . Briobacept (100 µg/mouse; i.p.; 3 times per week for 5 weeks) inhibits p52 generation and development of spontaneous lupus-like disease in NZB/WF1 mice ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Sifuentes Giraldo WA, et al. New targets in systemic lupus (part 2/2). *Reumatol Clin*. 2012 Sep-Oct;8(5):263-9.
- [2]. Liu Yunjie, et al. Research progress on the pathogenesis and drug targeting therapy of B lymphocyte stimulator-induced rheumatoid arthritis. 2011;22(33):3152-3154.
- [3]. La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. *Expert Opin Biol Ther*. 2010 Nov;10(11):1555-61.
- [4]. Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. *Immunity*. 2002 Oct;17(4):515-24.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA